ImpediMed (IPD) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional land owners, confirmation of quorum, and introductions of directors, management, and audit representatives.

• Agenda included chair's address, CEO presentation, SOZO market opportunity, BCRL update, cardiometabolic business, financials, strategy for the next year, general business Q&A, and formal business with voting on resolutions.

Financial performance review

• FY25 total revenue reached $12.7 million, up 23% from FY24, with SOZO core business revenue at $12.1 million, a 25% increase.

• Annual recurring revenue for SOZO core business rose 27% to $14 million.

• Gross profit margin remained strong at 86%, and cash balance at FY2025 close was $22.2 million.

• Patient tests increased 15% year-over-year, with 287,000 tests conducted.

• U.S. business accounted for 91% of BCRL revenue, with ARR growing at a three-year compound rate of 24%.

Board and executive committee updates

• Andrew Grant completed a year back on the board, now a full non-executive director for 2026.

• Board majority remains independent, with focus on governance, innovation, and strategic direction.

• Christine Emmanuel-Donnelly and McGregor Grant stood for reelection, highlighting expertise in IP, commercialization, and medical device growth.

• Audit and Risk Management Committee represented by Fiona Bones, with EY as independent auditor.